In contrast, anemia developing during SAH treatment (assessed by mean and nadir Hb values) showed significant associations at sufficient evidence level with the risk of cerebral vasospasm, infarction and poor outcome at discharge and follow-up. This evidence concerns the gene GSTM1 and anemia.